This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, R. G. Search for Related Content PubMed PubMed Citation Articles by Smith, R. G.

Development of Growth Hormone Secretagogues

The Huffington Center on Aging, Department of Molecular and Cellular Biology and Department of Medicine, Baylor College of Medicine, Houston, Texas 77030

Correspondence: Address all correspondence and requests for reprints to: Roy G. Smith, Ph.D., Huffington Center on Aging, Baylor College of Medicine, One Baylor Plaza, Room M320, Houston, Texas 77030-3498.

The GH secretagogues (GHS) were developed by reverse pharmacology. The objective was to develop small molecules with pharmacokinetics suitable for once-daily oral administration that would rejuvenate the GH/IGF-I axis. Neither the receptor nor the ligand that controlled pulse amplitude of hormone release was known; therefore, identification of lead structures was based on function. I reasoned that GH pulse amplitude could be increased by four possible mechanisms: 1) increasing GHRH release; 2) amplifying GHRH signaling in somatotrophs of the anterior pituitary gland; 3) reducing somatostatin release; and 4) antagonizing somatostatin receptor signaling. Remarkably, the GHS act through all four mechanisms to reproduce a young adult physiological GH profile in elderly subjects that was accompanied by increased bone mineral density and lean mass, modest improvements in strength, and improved recovery from hip fracture. Furthermore, restoration of thymic function was induced in old mice. The GHS receptor (GHS-R) was subsequently identified by expression cloning and found to be a previously unknown G protein-coupled receptor expressed predominantly in brain, pituitary gland, and pancreas. Reverse pharmacology was completed when the cloned GHS-R was exploited to identify an endogenous agonist (ghrelin) and a partial agonist (adenosine); ghsr-knockout mice studies confirmed that GHS are ghrelin mimetics.

This article has been cited by other articles:

				N. Moller and J. O. L. Jorgensen Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects Endocr. Rev., April 1, 2009; 30(2): 152 - 177. [Abstract] [Full Text] [PDF]

				R. Nass, S. S. Pezzoli, M. C. Oliveri, J. T. Patrie, F. E. Harrell Jr., J. L. Clasey, S. B. Heymsfield, M. A. Bach, M. L. Vance, and M. O. Thorner Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized Trial Ann Intern Med, November 4, 2008; 149(9): 601 - 611. [Abstract] [Full Text] [PDF]

				R. Nass, L. S. Farhy, J. Liu, C. E. Prudom, M. L. Johnson, P. Veldhuis, S. S. Pezzoli, M. C. Oliveri, B. D. Gaylinn, H. M. Geysen, et al. Evidence for Acyl-Ghrelin Modulation of Growth Hormone Release in the Fed State J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1988 - 1994. [Abstract] [Full Text] [PDF]

				M. G.-S. Frutos, L. Cacicedo, C. Fernandez, D. Vicent, B. Velasco, H. Zapatero, and F. Sanchez-Franco Insights into a role of GH secretagogues in reversing the age-related decline in the GH/IGF-I axis Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1140 - E1152. [Abstract] [Full Text] [PDF]

				A. Ben-Shlomo, O. Pichurin, N. J. Barshop, K. A. Wawrowsky, J. Taylor, M. D. Culler, V. Chesnokova, N.-A. Liu, and S. Melmed Selective Regulation of Somatostatin Receptor Subtype Signaling: Evidence for Constitutive Receptor Activation Mol. Endocrinol., October 1, 2007; 21(10): 2565 - 2578. [Abstract] [Full Text] [PDF]

				Y. Sun, J. M. Garcia, and R. G. Smith Ghrelin and Growth Hormone Secretagogue Receptor Expression in Mice during Aging Endocrinology, March 1, 2007; 148(3): 1323 - 1329. [Abstract] [Full Text] [PDF]

				M. Iantorno, H. Chen, J.-a Kim, M. Tesauro, D. Lauro, C. Cardillo, and M. J. Quon Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E756 - E764. [Abstract] [Full Text] [PDF]

				I. Garcia-Tornadu, M. Rubinstein, B. D Gaylinn, D. Hill, E. Arany, M. J Low, G. Diaz-Torga, and D. Becu-Villalobos GH in the dwarf dopaminergic D2 receptor knockout mouse: somatotrope population, GH release, and responsiveness to GH-releasing factors and somatostatin. J. Endocrinol., September 1, 2006; 190(3): 611 - 619. [Abstract] [Full Text] [PDF]

				H. Jiang, L. Betancourt, and R. G. Smith Ghrelin Amplifies Dopamine Signaling by Cross Talk Involving Formation of Growth Hormone Secretagogue Receptor/Dopamine Receptor Subtype 1 Heterodimers Mol. Endocrinol., August 1, 2006; 20(8): 1772 - 1785. [Abstract] [Full Text] [PDF]